PURPOSE: To determine the toxicity and pharmacokinetics of recombinant heparin-binding epidermal growth factor-like growth factor in female Sprague Dawley rats following intra-bladder and intravenous administration. MATERIALS AND METHODS: rhHB-EGF was administered once daily for 6 or 27 days at doses of 3, 10, or 30 microg/kg. 125I-rhHB-EGF was administered on day 7 or 28 for pharmacokinetic analysis. Toxicity was assessed by general appearance and behavior, gross necropsy, blood chemistry and microscopic evaluation. RESULTS: Plasma AUCss of [125I] rhHB-EGF equivalents following IB administration for 7 days were 4.28+/-2.29, 7.75+/-2.70, and 7.11+/-1.42 ng ml(-1) h(-1) at doses of 3, 10, and 30 microg/kg, respectively. Following IV administration, the AUCss on day 7 increased from 27.0+/-2.66 to 124+/-5.09 and 385.11+/-7.57 ng ml(-1) h(-1) with increasing the dose from 3 to 10 and 30 microg/kg. Similar AUCss data was obtained after 28 day administration. No toxicity was evident upon gross examination. Histologic examination revealed subacute inflammation and lymphocytic infiltration of the urinary bladder in animals from all groups dosed by the IB route. CONCLUSIONS: Plasma and bladder concentrations of recombinant human [125I] rhHB-EGF equivalents were significantly lower following the IB route than following IV administration. Histologic tissue examination indicated no toxicity attributable to rhHB-EGF.
PURPOSE: To determine the toxicity and pharmacokinetics of recombinant heparin-binding epidermal growth factor-like growth factor in female Sprague Dawley rats following intra-bladder and intravenous administration. MATERIALS AND METHODS: rhHB-EGF was administered once daily for 6 or 27 days at doses of 3, 10, or 30 microg/kg. 125I-rhHB-EGF was administered on day 7 or 28 for pharmacokinetic analysis. Toxicity was assessed by general appearance and behavior, gross necropsy, blood chemistry and microscopic evaluation. RESULTS: Plasma AUCss of [125I] rhHB-EGF equivalents following IB administration for 7 days were 4.28+/-2.29, 7.75+/-2.70, and 7.11+/-1.42 ng ml(-1) h(-1) at doses of 3, 10, and 30 microg/kg, respectively. Following IV administration, the AUCss on day 7 increased from 27.0+/-2.66 to 124+/-5.09 and 385.11+/-7.57 ng ml(-1) h(-1) with increasing the dose from 3 to 10 and 30 microg/kg. Similar AUCss data was obtained after 28 day administration. No toxicity was evident upon gross examination. Histologic examination revealed subacute inflammation and lymphocytic infiltration of the urinary bladder in animals from all groups dosed by the IB route. CONCLUSIONS: Plasma and bladder concentrations of recombinant human [125I] rhHB-EGF equivalents were significantly lower following the IB route than following IV administration. Histologic tissue examination indicated no toxicity attributable to rhHB-EGF.
Authors: Y Murayama; J Miyagawa; S Higashiyama; S Kondo; M Yabu; K Isozaki; Y Kayanoki; S Kanayama; Y Shinomura; N Taniguchi Journal: Gastroenterology Date: 1995-10 Impact factor: 22.682
Authors: N Ito; S Kawata; S Tamura; S Kiso; H Tsushima; D Damm; J A Abraham; S Higashiyama; N Taniguchi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1994-01-14 Impact factor: 3.575
Authors: Susan K Keay; Zoltan Szekely; Thomas P Conrads; Timothy D Veenstra; Joseph J Barchi; Chen-Ou Zhang; Kristopher R Koch; Christopher J Michejda Journal: Proc Natl Acad Sci U S A Date: 2004-07-28 Impact factor: 11.205
Authors: G Y Kim; G E Besner; C L Steffen; D W McCarthy; M T Downing; M H Luquette; M S Abad; D R Brigstock Journal: Biol Reprod Date: 1995-03 Impact factor: 4.285
Authors: J A Abraham; D Damm; A Bajardi; J Miller; M Klagsbrun; R A Ezekowitz Journal: Biochem Biophys Res Commun Date: 1993-01-15 Impact factor: 3.575